Skip to content
DataLookout
Menu

NCT06484920

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

StatusTerminated
PhasePhase 2
SponsorRita Assi
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Loss of research support Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Final enrollment: 1 participants, 4% of the 24 planned
    • Results posted: Nov 17, 2026
    • Eligibility criteria expanded, about 44 words
    • Primary completion date changed from estimate of Dec 2027 to Jun 3, 2025
    • Secondary endpoints revised (3)
    • Site details revised at 2 of 2 sites
  2. Minor Site contacts updated at 1 of 2 sitesv6
  3. Notable Eligibility criteria revised
    • Site contacts updated at 2 of 2 sites
    v5
  4. Minor Start date changed from estimate of Oct 2024 to Nov 18, 2024
    • Site contacts updated at 1 of 2 sites
    v4
  5. Notable Start date: Aug 2024 to Oct 2024
    • Study completion date: Dec 2030 to Sep 2029
    • Site contacts updated at 2 of 2 sites
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2024 to Aug 2024
    • Site details revised at 2 of 2 sites
    v2
  7. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety: Percentage of Patients With Treatment-Related Adverse Events
Timeframe: On treatment date to end of study (up to 1 month)

Secondary (3)

Overall Response Rate (Percentage of Patients With Complete Response or Partial Response)
Complete Remission Rate
Change in Patient Derived Myeloid-derived Suppressor Cells (MDSC)

Arms and interventions

ATRA and PembrolizumabExperimental

Patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 ATRA orally for 3 days surrounding each of the first four infusions of pembrolizumab (day -1, day 0, day +1).

Drugs: ATRA, Pembrolizumab

Sites

2 sites in 1 country